For instance, increased expression of ARPC1B was linked to enhanced sensitivity to Dabrafenib, Vemurafenib, Encorafenib, ABT-199, and Selumetinib in CRC patients. The gene discussed is ARPC1B; the disease is colorectal carcinoma.